We set out to ascertain if there is a consensus in elective orthopaedic practice for the screening and management of MRSA. A questionnaire was distributed to all British Orthopaedic Association Linkmen, with prepaid return envelopes.

A response rate of 60% (159 of 250) was recorded. 62% do have a screening policy in practice: all admissions (44%), high risk patients only (22%), only patients for joint replacement (12%), both patients for joint replacement and patients at high risk of carriage (21%). Eradication therapy is used in a MRSA - positive patient prior to joint replacement surgery by 91%, following which the MRSA status would be checked by 88%. The efficacy of eradication would be confirmed by obtaining: one set (29%), two sets (13%), and three sets (49%) of negative swabs, prior to proceeding with surgery. A 2nd generation Cephalosporin (77%), followed by Teicoplanin/Vancomycin (16%) are in routine use for antibiotic prophylaxis.

The majority of responders have adopted a practice of screening patients; however, significant differences exist in the population that is selected for screening. Eradication in MRSA positive patients is a common practice, but there is variation in the number of subsequent screens performed. Cephalosporins remain the antibiotic of choice for prophylaxis but first line therapeutic agents are also being used which may have implications for resistance. These variations can be partly attributed to the lack of evidence from which practical guidelines can be drafted, as highlighted by national guidelines published in 1998. Until further research is done into the cost effectiveness of screening and the further management of MRSa we have to rely on strict adherence to infection control practices, and appropriate use of antibiotics.